Glaukos Co. (NYSE:GKOS – Get Free Report) Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Glaukos Price Performance
Glaukos stock traded down $0.24 during trading hours on Wednesday, hitting $125.50. 443,954 shares of the stock were exchanged, compared to its average volume of 585,500. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. The stock has a market capitalization of $6.90 billion, a P/E ratio of -43.58 and a beta of 1.02. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60. The business’s 50-day moving average is $124.18 and its two-hundred day moving average is $109.64.
Glaukos (NYSE:GKOS – Get Free Report) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same period in the prior year, the business earned ($0.55) earnings per share. Glaukos’s quarterly revenue was up 19.0% on a year-over-year basis. Equities research analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.
Hedge Funds Weigh In On Glaukos
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. BTIG Research upped their target price on shares of Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Truist Financial reissued a “buy” rating and issued a $145.00 target price (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Finally, StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $129.82.
Read Our Latest Analysis on Glaukos
Glaukos Company Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
- Five stocks we like better than Glaukos
- What Do S&P 500 Stocks Tell Investors About the Market?
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- P/E Ratio Calculation: How to Assess Stocks
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Which Wall Street Analysts are the Most Accurate?
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.